Dabrafenib + Trametinib in Pediatric Glioma With BRAF V600 Mutations
In a phase 2 trial of 110 pediatric patients with low-grade glioma with BRAF V600 mutations, the combination of dabrafenib plus trametinib had significantly more responses, longer
In a phase 2 trial of 110 pediatric patients with low-grade glioma with BRAF V600 mutations, the combination of dabrafenib plus trametinib had significantly more responses, longer
An expert panel has updated the guideline of the American Society of Clinical Oncology for practical assessment and management of vulnerabilities in older adults receiving
A novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity, oral mezigdomide showed “promising efficacy in patients with heavily pretreated multiple myeloma,
Approximately one-third of patients with advanced alveolar soft part sarcoma (ASPS) — a rare soft-tissue sarcoma with a poor prognosis and no established therapy —
In a phase 1/2 trial, oral mezigdomide plus dexamethasone showed efficacy in patients with heavily pretreated multiple myeloma. Mezigdomide acts through protein degradation that binds
Single-agent therapy with the covalent KRAS G12C inhibitor divarasib (GDC-6036) “resulted in durable clinical responses across KRAS G12C–positive tumors, with mostly low-grade adverse events,” the GO42144 study
The Childhood Cancer Data Initiative (CCDI), launched in 2019 at the National Cancer Institute, could provide a model for adults, authors write, “transforming both clinical
In the phase 3 Vorasidenib in Glioma (INDIGO) trial, patients with isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas had significantly better progression-free survival and time to
Two studies examine the use of perioperative immunotherapy in patients with early-stage and stage 3 non–small-cell lung cancer (NSCLC) with pembrolizumab and nivolumab, respectively. “Among patients
Atorvastatin reduced the incidence of cardiac dysfunction among patients with lymphoma treated with anthracycline-based chemotherapy in the STOP-CA (Statins to Prevent the Cardiotoxicity of Anthracyclines)